||Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 3.
Aizawa, Yuta相澤, 悠太
学位の種類: 博士（医学）. 報告番号: 甲第4126号. 学位記番号: 新大院博（医）甲第693号. 学位授与年月日: 平成28年3月23日
Emerging Infectious Diseases. 2015, 21(11), 1966-1972.
Human parechovirus type 3 (HPeV3) is an emerging patho¬gen that causes sepsis and meningoencephalitis in young infants. To test the hypothesis that maternal antibodies can protect this population, we measured neutralizing antibody titers (NATs) to HPeV3 and other genotypes (HPeV1 and HPeV6) in 175 cord blood samples in Japan. The seroposi¬tivity rate (>1:32) for HPeV3 was 61%, similar to that for the other genotypes, but decreased significantly as ma¬ternal age increased (p<0.001). Furthermore, during the 2014 HPeV3 epidemic, prospective measurement of NATs to HPeV3 in 45 patients with severe diseases caused by HPeV3 infection showed low NATs (<1:16) at onset and persistently high NATs (>1:512) until age 6 months. All intra¬venous immunoglobulin samples tested elicited high NATs to HPeV3. Our findings indicate that maternal antibodies to HPeV3 may help protect young infants from severe dis¬eases related to HPeV3 and that antibody supplementation may benefit these patients.